Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.